AcouSort receives SEK 1.25 million in Vinnova funding for the IndiCell project. The aim of the project is to enable the transition of new stem cell therapies from research to a clinical setting. The project is planned to run for five years and generate revenues of SEK 1.25 million for AcouSort.
– We are very excited to start this project where we will contribute with our unique acoustic technology to introduce clinical workflows for individualized cell therapy. Together with the Blue4Therapy project, we now have two publicly funded projects related to cell therapies. This means we can further accelerate our application development for stem cell-related clinical therapies, an area with very high commercial potential, says AcouSort’s CEO Torsten Freltoft.
Diseases that are currently incurable will in the future be treated with so-called induced pluripotent stem cells, which are extracted from the patient’s own healthy cells. The overall aim of IndiCell is to build a unique and strong environment focused on such personalised cell therapies, to reduce the risks and overcome the barriers that arise in the transition from basic research to innovation and on to clinical applications. The project will build an innovation environment consisting of actors from three different sectors; academic researchers (Lund University, Karolinska Institutet and KTH), healthcare (Vecura, SUS) and small and medium-sized enterprises (BioLamina, AcouSort, MagicBioprocessing). AcouSort’s role will be to develop standard procedures for cell handling based on acoustic separation. IndiCell is one of 11 innovation environments in precision healthcare that Vinnova is investing in, with the aim of paving the way for more preventive, accurate and equitable healthcare and strengthening Sweden as a life science nation.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
AcouSort AB (organisationsnummer 556824-1037) is a technology company focused on medtech/biotech, based in Lund. The company has developed a platform technology around acustophoresis, which is a new and innovative method for separating, enriching and purifying cells and other particles for bioanalysis, using ultrasound. Separation and purification of cells is a key part of research and diagnostics in several major disease areas, such as cancer and sepsis (blood poisoning). The company’s initial business idea is to develop scientific instruments based on acoustophores for non-clinical research on biological particles and cells. In addition, the company has a number of development partnerships with leading biotech companies and has a vision to become a leading supplier of OEM products based on acousto-phores for cell and particle handling in clinical application areas.